CN113891711A - 用于治疗神经退行性疾病的化合物 - Google Patents
用于治疗神经退行性疾病的化合物 Download PDFInfo
- Publication number
- CN113891711A CN113891711A CN202080020703.4A CN202080020703A CN113891711A CN 113891711 A CN113891711 A CN 113891711A CN 202080020703 A CN202080020703 A CN 202080020703A CN 113891711 A CN113891711 A CN 113891711A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- radical
- cycloalkyl
- halogen
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种具有取代的双环结构的化合物，其药学上可接受的盐、立体异构体、溶剂化物、多晶型、互变异构体、同位素化合物、代谢产物或前药，在制备用于预防或治疗聚谷氨酰胺(polyQ)相关的疾病的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (16)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019101806747 | 2019-03-11 | ||
| CN201910180674.7A CN111671755A (zh) | 2019-03-11 | 2019-03-11 | 用于治疗神经退行性疾病的化合物 |
| CN201911000198.2A CN112759554A (zh) | 2019-10-21 | 2019-10-21 | 用于治疗神经退行性疾病的化合物 |
| CN2019110001982 | 2019-10-21 | ||
| PCT/CN2020/078779 WO2020182144A1 (zh) | 2019-03-11 | 2020-03-11 | 用于治疗神经退行性疾病的化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113891711A true CN113891711A (zh) | 2022-01-04 |
Family
ID=72427189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080020703.4A Pending CN113891711A (zh) | 2019-03-11 | 2020-03-11 | 用于治疗神经退行性疾病的化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220249433A1 (zh) |
| EP (1) | EP3954368A4 (zh) |
| JP (1) | JP2022525151A (zh) |
| CN (1) | CN113891711A (zh) |
| WO (1) | WO2020182144A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2023104170A1 (en) * | 2021-12-08 | 2023-06-15 | Hangzhou Jijing Pharmaceutical Technology Limited | Compounds for treating polyq-related neurodegenerative disorders |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021210A2 (en) * | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| WO2010075286A1 (en) * | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
| CN102499917A (zh) * | 2011-10-25 | 2012-06-20 | 澳门大学 | 吲哚酮类化合物在制备神经保护药物中的应用 |
| WO2018203559A1 (ja) * | 2017-05-02 | 2018-11-08 | 国立大学法人京都大学 | ポリグルタミン病に関する医薬組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2323697A2 (en) * | 2008-07-24 | 2011-05-25 | Siemens Medical Solutions USA, Inc. | Imaging agents useful for identifying ad pathology |
| US8741259B2 (en) * | 2008-10-20 | 2014-06-03 | Marvin C. Gershengorn | Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists |
-
2020
- 2020-03-11 JP JP2021555240A patent/JP2022525151A/ja active Pending
- 2020-03-11 EP EP20771013.8A patent/EP3954368A4/en active Pending
- 2020-03-11 WO PCT/CN2020/078779 patent/WO2020182144A1/zh unknown
- 2020-03-11 CN CN202080020703.4A patent/CN113891711A/zh active Pending
- 2020-03-11 US US17/437,976 patent/US20220249433A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021210A2 (en) * | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| WO2010075286A1 (en) * | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
| CN102499917A (zh) * | 2011-10-25 | 2012-06-20 | 澳门大学 | 吲哚酮类化合物在制备神经保护药物中的应用 |
| WO2018203559A1 (ja) * | 2017-05-02 | 2018-11-08 | 国立大学法人京都大学 | ポリグルタミン病に関する医薬組成物 |
Non-Patent Citations (1)
| Title |
|---|
| GANG LI等: "Discovery and Optimization of Novel 3-Piperazinylcoumarin Antagonist of Chemokine-like Factor 1 with Oral Antiasthma Activity in Mice", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, pages 1743 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022525151A (ja) | 2022-05-11 |
| EP3954368A4 (en) | 2023-04-26 |
| EP3954368A1 (en) | 2022-02-16 |
| US20220249433A1 (en) | 2022-08-11 |
| WO2020182144A1 (zh) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6959650B2 (ja) | アルデヒドコンジュゲートおよびその使用 | |
| JP6913698B2 (ja) | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 | |
| EP1845970B1 (en) | Tumor necrosis factor inhibitors | |
| JP5736421B2 (ja) | 生理学的過程の調節およびこれに有用な薬剤 | |
| KR20170008320A (ko) | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 | |
| CA2664099A1 (en) | Methods and compositions for treating amyotrophic lateral sclerosis (als) | |
| EP2633868A1 (en) | Combination of alpha 7 nicotinic agonists and antipsychotics | |
| US11414379B2 (en) | SPAK kinase inhibitors as neuroprotective agents | |
| JP2022105159A (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| US20230138663A1 (en) | Eaat2 activators and methods of using thereof | |
| CN113891711A (zh) | 用于治疗神经退行性疾病的化合物 | |
| TW201444860A (zh) | 脲嘧啶核苷衍生物、組合物及使用方法 | |
| ES2812800T3 (es) | Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías | |
| EA030374B1 (ru) | Производные нафтиридиндиона | |
| WO2015047982A2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| CN111671755A (zh) | 用于治疗神经退行性疾病的化合物 | |
| ES2925550T3 (es) | Trastornos neurodegenerativos | |
| CN112759554A (zh) | 用于治疗神经退行性疾病的化合物 | |
| CN115515682A (zh) | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
| JP2019501972A (ja) | Ｔｄｐ−４３タンパク質症の治療のためのタクロリムス | |
| US11491150B2 (en) | Organic compounds | |
| RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
| WO2020199757A1 (zh) | 磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
| JP2022519779A (ja) | エモキシピンの多価誘導体 | |
| KR20010029658A (ko) | 뇌의 아세틸콜린 방출 증강제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |